The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
Increases speed to market for drug developers working on nucleic acid therapeutics
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
The cornerstone of the quality ecosystem is the implementation of the Quality Control Orders
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
The biosimilar Ustekinumab has been developed and manufactured by the company
The order, part of an international framework agreement is to be executed between February to April, 2025
Subscribe To Our Newsletter & Stay Updated
